DoubleLine’s Jeffrey Gundlach sees just one rate slash this year as the Fed keeps up inflation combat

DoubleLine’s Jeffrey Gundlach sees just one rate slash this year as the Fed keeps up inflation combat


Critical Details
  • DoubleLine Money CEO Jeffrey Gundlach said Wednesday that he now sees no far more than one interest charge minimize this yr.
  • The observed preset earnings investor said the most essential second from the Fed’s plan celebration on Wednesday was when the central bank’s Chair Jerome Powell all but dominated out the probability of a price hike.
  • Treasury yields dropped to their session lows and shares shot to session highs as Powell said the up coming policy go will not be a fee raise.



Supply

Under threat from Trump, Wall Street banks wager they can fend off credit card price controls
Finance

Under threat from Trump, Wall Street banks wager they can fend off credit card price controls

Key Points U.S. banks including JPMorgan Chase and Citigroup showed no signs of capitulation to President Donald Trump’s mandate of a 10% cap on credit card interest rates. Five days after the original threat, bankers and their lobbyists told CNBC that they have yet to receive any formal or written guidance from the Trump administration […]

Read More
Airlines to save big money on fuel as new weight loss pills gain popularity, Wall Street says
Finance

Airlines to save big money on fuel as new weight loss pills gain popularity, Wall Street says

Celsopupo | Istock | Getty Images Wall Street is finding an unexpected beneficiary of America’s weight loss boom: airlines. With the first GLP-1 weight loss drug now available in pill form, analysts at Jefferies say broad adoption across society could quietly lower fuel bills — airlines’ single largest cost — and lift earnings for the […]

Read More
Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more
Finance

Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more

Check out the companies making headlines in midday trading. Biogen — The biotech’s stock tumbled more than 4% after the company warned it would need to take a $222 million pretax charge in the fourth quarter. The company said the charge, which includes research-and-development expenses and milestone payments, will lower its net income by about […]

Read More